The Centre for Drug Candidate Optimisation (CDCO) is a collaborative research centre. We provide drug candidate optimisation services to accelerate and enhance the drug discovery and development process.
Drug development is often an expensive process. We work with local researchers, biotechnology companies and international not-for-profits to identify suitable compounds for future clinical development.
Because of our work, more than 15 new drug candidates have progressed into clinical development. This includes a new anti-malarial drug candidate recognised by the Bill and Melinda Gates foundation. We have also received numerous drug discovery awards.
We optimise drug candidates to improve their safety and effectiveness. We do this by analysing the physicochemical, pharmacokinetic and bioavailability properties of drugs. In particular we look at the ADME (absorption, distribution, metabolism and elimination) properties to find out which drug molecules work best in the body.
Our centre is located within the Monash Institute of Pharmaceutical Sciences (MIPS).
- Physicochemical profiling
- Drug permeability
- Drug metabolism and metabolite profiling
- Metabolic drug-drug interactions
- Bioavailability and pharmacokinetics
- Preclinical formulation development
- Solid state characterisation and salt selection
- Stability testing and impurity profiling
- Quantitative bioanalysis
Our key technology
- Six LC/MS instruments coupled with UPLC (single and quadruple MS; time of flight MS)
- Automated small animal in vivo blood sampling using BASI Culex™
- In silico and in vitro methods for profiling physiochemical properties
- Plate-based assays for CYP450 metabolic stability, metabolite profiling and metabolic drug interactions
- Cell culture facilities for permeability assessment (Caco-2 or MDCK)
You can access this facility via:
- Collaborative research
- Fee for service